Hepatocellular carcinoma: considerations for managed care professionals

Liver cancer is the most rapidly increasing cancer in the United States and is associated with a high cancer-related mortality. Seventy-five percent of liver cancers are hepatocellular carcinoma (HCC) resulting from cirrhosis. Patients are typically diagnosed late in the disease, with a relatively s...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of managed care Vol. 26; no. 10 Suppl; pp. S220 - S226
Main Author Bobolts, Laura R
Format Journal Article
LanguageEnglish
Published United States 01.10.2020
Subjects
Health administration
Online AccessGet full text

Cover

More Information
Summary:Liver cancer is the most rapidly increasing cancer in the United States and is associated with a high cancer-related mortality. Seventy-five percent of liver cancers are hepatocellular carcinoma (HCC) resulting from cirrhosis. Patients are typically diagnosed late in the disease, with a relatively small percentage eligible for curative treatments. Despite the addition of several new therapies for advanced HCC, the 5-year survival rate is just 18%. The direct and indirect costs of HCC are substantial, and are expected to increase with the rise in disease incidence as well as a growing number of high-cost therapies entering the market. There are opportunities to improve the quality of care for patients with HCC through implementation of value-based reimbursement principles and pharmacist involvement in care.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1088-0224
1936-2692
DOI:10.37765/AJMC.2020.88513